Myocardial Infarction (MI) Treatment

Global Myocardial Infarction (MI) Treatment Market to Reach US$2.1 Billion by 2030

The global market for Myocardial Infarction (MI) Treatment estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Antiplatelet Agents, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$954.6 Million by the end of the analysis period. Growth in the Glycoprotein IIb / IIIa Inhibitors segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$481.5 Million While China is Forecast to Grow at 5.9% CAGR

The Myocardial Infarction (MI) Treatment market in the U.S. is estimated at US$481.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$434.9 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Myocardial Infarction (MI) Treatment Market - Key Trends and Drivers Summarized

Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a part of the heart is blocked for a long enough time that part of the heart muscle is damaged or dies. The most common cause of MI is the buildup of fatty deposits on the walls of coronary arteries, which form plaques. When these plaques rupture, a blood clot can form and obstruct the blood flow. Immediate treatment is crucial to restore blood flow and minimize heart damage. The primary treatment for MI includes medications such as antiplatelets, anticoagulants, thrombolytics, beta-blockers, and ACE inhibitors. These drugs help dissolve clots, reduce the heart`s workload, and prevent further clot formation. In addition to medication, invasive procedures like angioplasty and stent placement, as well as coronary artery bypass grafting (CABG), are often necessary to reopen blocked arteries and restore blood flow.

Advancements in technology have significantly improved the outcomes of MI treatment. The development of drug-eluting stents, which release medication to prevent artery re-blockage, has revolutionized angioplasty procedures. Moreover, the use of advanced imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) allows for precise assessment of arterial blockages and better planning of interventions. Telemedicine and remote monitoring technologies have also made it possible for healthcare providers to monitor patients` heart health more closely and respond quickly to signs of a potential MI. Furthermore, the implementation of comprehensive cardiac rehabilitation programs, which include exercise training, dietary counseling, and psychological support, has proven to be effective in improving the long-term outcomes and quality of life for MI patients.

The growth in the myocardial infarction treatment market is driven by several factors. Advances in medical technology, such as the development of minimally invasive surgical techniques and more effective drug therapies, are propelling market expansion. The increasing prevalence of cardiovascular diseases due to aging populations and lifestyle factors like poor diet, lack of exercise, and smoking is also driving demand for MI treatments. Additionally, heightened awareness about the importance of early diagnosis and intervention, supported by public health initiatives and education campaigns, is leading to more timely and effective treatments. The rise of personalized medicine, which tailors treatment plans to individual patient profiles based on genetic, environmental, and lifestyle factors, is another significant driver. Innovations in wearable health technologies and mobile health applications that facilitate continuous monitoring and early detection of heart issues are further contributing to market growth. Moreover, robust healthcare infrastructure in developed regions and improving access to healthcare services in emerging markets are expanding the reach of MI treatments. As healthcare providers continue to adopt new technologies and methods, the market for myocardial infarction treatments is expected to experience sustained growth.

SCOPE OF STUDY:

The report analyzes the Myocardial Infarction (MI) Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Type (Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers, Other Drug Types); Distribution Channel (Hospital Pharmacies, Drug Stores, Online Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 53 Featured) -

• A. Menarini Industrie Farmaceutiche Riunite Srl
• Amgen, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Bayer AG
• Biocardia, Inc.
• Boehringer Ingelheim International GmbH
• CellProthera
• CSL Ltd.
• Daiichi Sankyo Co., Ltd.
• Faraday Pharmaceuticals
• Kancera AB
• Nordic Bioscience A/S
• Tenaya Therapeutics
• Viatris Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.